备注:
库存充足,如需更大包装,请联系销售人员,大包装有极大的折扣优惠!
详细介绍
l 基本信息 |
产品名称 | 氯硝柳胺(Niclosamide) |
一般描述 | Niclosamide(氯硝柳胺) is an orally bioavailable chlorinated salicylanilide, with anthelmintic and potential antineoplastic activity. |
别 称 | 5-chloro-N-(2-chloro-4-nitrophenyl)-2-hydroxybenzamide |
纯 度 | ≥98%(HPLC) | CAS NO. | 50-65-7 |
分子式 | C13H8Cl2N2O4 | 分子量 | 327.12 |
适用范围 | 生物试剂,适用于细胞培养等 |
l 理化信息 |
外 观 | 黄色固体 |
溶解性(25℃) | DMSO | Insoluble |
DMF | ~12
mg/mL |
水 | Insoluble |
l 生物学信息 |
生物活性/药理作用 | Niclosamide is an antihelminth used against tapeworm infections. It may act by the uncoupling of the electron transport chain to ATP synthase. The disturbance of this crucial metabolic pathway prevents creation of adenosine tri-phosphate (ATP), an essential molecule that supplies energy for metabolism. Niclosamide is an orally bioavailable
chlorinated salicylanilide, with anthelmintic and potential antineoplastic activity. Upon oral administration, niclosamide specifically induces degradation of the androgen receptor (AR) variant V7 (AR-V7) through the proteasome-mediated pathway. This downregulates the of the AR variant, inhibits AR-V7-mediated tranional activity, and reduces AR-V7 recruitment to the prostate-specific antigen (PSA) gene promoter. Niclosamide also prevents AR-V7-mediated STAT3 phosphorylation and activation. This inhibits AR/STAT3-mediated signaling and prevents of STAT3 target genes. Altogether, this may inhibit growth of AR-V7-overexpressing cancer cells. The AR-V7 variant, which is encoded by contiguous splicing of AR exons 1/2/3/CE3, is upregulated in a variety of cancer cell types, and is associated with both cancer progression and resistance to AR-targeted therapies. |
l 包装与存储 |
包 装 | 1g |
存储温度 | 0-5℃ |
l 注意事项及免责声明 |
本产品仅用于实验研究,不得作为药物使用,不得用于家用或其它用途。 |
l 参考文献 |
1. http://www.drugbank.ca 2. https://ncit.nci.nih.gov 3. https://www.ncbi.nlm.nih.gov |